Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.56 |
| ▸ | DRD3 | P35462 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028962 | 0.92 | DRD3 (0.46) | CNR2DRD3 | |
| SCHEMBL6243987 | 0.88 | CNR2 (0.53) | CNR2DRD3LTA4H | |
| SCHEMBL5028956 | 0.83 | CNR2 (0.47) | CNR2DRD3DRD4 | |
| SCHEMBL2295815 | 0.80 | DRD3 (0.61) | CNR2DRD3DRD4 | |
| SCHEMBL2294841 | 0.80 | DRD3 (0.61) | CNR2DRD3DRD4 | |
| SCHEMBL2297490 | 0.76 | DRD3 (0.58) | CNR2DRD3 | |
| SCHEMBL2293451 | 0.76 | DRD3 (0.58) | CNR2DRD3 | |
| SCHEMBL5030220 | 0.75 | DRD3 (0.43) | CNR2DRD3DRD4 | |
| SCHEMBL6444671 | 0.75 | CNR2 (0.44) | CNR2DRD3RXRB | |
| SCHEMBL2298390 | 0.75 | DRD4 (0.67) | CNR2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1226128-B1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6716845-B2 | Barbituric acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1383746-A2 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-28 | — | — | EP | disclosed |
| US-6498252-B1 | Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | HOFFMANN-LA ROCHE INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020187991-A1 | Barbituric acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| WO-2002079170-A2 | PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187991-A1 | Barbituric acid derivatives | GABBR1, GABBR2, TUBB6 | CNR2 2063/4885DRD3 1271/4885DRD4 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.